In this article, Dave Elder delves deeper into some ongoing developments in topic areas highlighted in European Pharmaceutical Review (EPR) during 2023.
N-Nitrosamines
By far the biggest issue bedevilling industry during 2023 was the continuing N-nitrosamine contamination saga, which was covered in the third issue of EPR 2023.1 Some five years after the initial NDMA (N-nitrosodimethylamine) contamination issue2 initially affecting valsartan drug substance, then other active pharmaceutical ingredients (APIs), eg, sartans, ranitidine, metformin, etc; the toxic short alkyl chain N-nitrosamine issue appears, if not resolved, then well on the way to resolution. In contrast, NDSRIs (N-Nitrosamine drug substance-related impurities) are still a burgeoning issue with many new NDSRIs being reported on a weekly basis.
During 2023, there were five revisions to the European Medicines Agency’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products.3 This serves to highlight the rapidly changing nature of the problem.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
The major take-home message of these ongoing regulatory changes is the realisation that the vast majority of NDSRIs are significantly less toxic than their short alkyl change ‘cousins’, ie, NDMA.4 The use of CPCA assessments allows for the assignment of scientifically justifiable higher acceptable intakes (AIs), without impacting patient safety. Thus, for example, N-nitroso varenicline (NNV) was initially assigned an AI of 37 ng/day even though its molecular size (bridged ring heterocycle) and molecular weight (279.28 g/mol) made it extremely unlikely that NNV would be this toxic, ie, 37 ng/day: that is nearly three times more toxic than NDMA (AI 96 ng/day). Using the CPCA approach, the AI for NNV was re-established at 400 ng/day (ie, over 10X greater) by the EMA, which is aligned with literature values based on structural similarity.5
During 2023, there were five revisions to the European Medicines Agency’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products.3 This serves to highlight the rapidly changing nature of the problem.
In addition, other researchers have claimed that the AIs should be modified to include stoichiometric adjustments, ie, addressing the pronounced differences in molecular weight (MW) between the reference mutagen(s) (typically small MW nitrosamines) and the NDSRI, which have much higher MWs: two-three times greater.6 The CPCA is a pragmatic, science-based approach which ensures that control strategies are more deliverable as method sensitivity/robustness considerations are more easily addressed.
During August 2023 the FDA also updated its guidance for NDSRIs7 and it was closely aligned (but not identical) to EMA’s evolving guidance.3 Differences include that potency category 1 in FDA’s CPCA approach is 26.5 ng/day, compared to EMA which is 18 ng/day. Also, EMA has applied CPCA to over-ride historically assigned AIs, while in some cases FDA has retained those historical limits, eg, NNV8 is still 37 ng/day in US. In these cases, FDA has used structure activity relationships to support the identification of a robustly tested surrogate that is similar in structure and reactivity, ie, read across, to the NDSRI, to generate an estimate of carcinogenic potency from which an AI limit can be scientifically determined. The NNV AI limit is therefore based on the surrogate, N-nitroso-1,2,3,6-tetrahydropyridine (NTHP). FDA has also published the AIs of some 265 NDSRIs.8 Using this list, approximately two-thirds (68 percent) showed strong confidence scores for accurate CPCA potency class predictions. In contrast, only 8 percent showed poor confidence in CPCA potency class predictions and this was typically based on the presence of uncommon structural features that activated or deactivated the molecule.9
ICH M7(R2)10 indicates that, “Higher acceptable intakes may be justified when human exposure to the impurity will be much greater from other sources, eg, food or endogenous metabolism (eg, formaldehyde)”. Regulators have struggled with the implications of this guidance as applied to N-nitrosamines given that many foods contain appreciable levels of N-nitrosamines and N-nitrosamines can be endogenously formed from the parent amine and endogenously generated nitrite. Thus, NDSRIs could be generated endogenously.11
In EPR Issue 2 2023,12 the clinical risk-benefit of smoking cessation products was examined. FDA’s AI limit of 37 ng/day for NNV in varenicline (a smoking cessation product) seems increasingly at odds with the huge exposure that patients experience from tobacco-specific nitrosamines (TSNAs); the clear health benefits of stopping smoking and avoiding excessive TSNA exposure seem unfavourably compared with a very constraining AI that has led many manufacturers to exit this market, leading to drug shortages.13
a coherent framework is needed for the derivation of harmonised AIs for novel nitrosamines without robust carcinogenicity data. It is to be hoped that this will be addressed by an update of the ICH M7(R2) guidance during 2024
ICH M7(R2)10 currently provides some guidance to establish AIs for mutagenic impurities. However, AIs for cohort of concern (CoC) mutagenic impurities, eg, N-nitrosamines, are not presently covered. At this current time, the risks posed by N-nitrosamine impurities in medicines have been addressed on a case-by-case basis with some divergence evident between different regulatory authorities, eg, NNV [400 ng/day (EMA) vs 37 ng/day (FDA)]. However, a coherent framework is needed for the derivation of harmonised AIs for novel nitrosamines without robust carcinogenicity data. It is to be hoped that this will be addressed by an update of the ICH M7(R2) guidance during 2024.
Quality risk management
During October 202314 the update to ICH Q9(R1)15 (quality risk management) was discussed. This ICH Q9 revision appears to have been primarily driven by EMA16 who highlighted that “uncertainties and gaps have become apparent during risk assessments for a high number of submissions”. This was particularly apparent in the risk-based decision making arising during the valsartan nitrosamine contamination crisis. It was concluded that an additional focus on “formality, risk-based decision making, subjectivity, and product availability risks”14 was required.
However, the greatest issue with risk assessments still appears to be subjectivity, and the bias inherent in all risk-based decision making. In the valsartan N-nitrosamine contamination issue, the biggest risk was the formation of hydrazoic acid, a byproduct of the sodium azide-mediated cyclisation of the tetrazole ring.16 Hydrazoic acid is a toxic, explosive gas and presents a significant worker-safety risk during manufacture of valsartan drug substance. This, in turn, prompted the use of sodium nitrite as an azide quenching agent, which in turn presents a potential high risk of nitrosamine formation. Risk assessment teams when faced with a confirmed high risk compared to a potential high risk will always prioritise the real risk, especially when the potential risk at that time has not yet been fully explored and nitrosamine exposure from other sources, eg, environment, food, water and endogenous formation, are comparatively high.17
Accelerating drug development
The first issue of 2023,18 dealt with accelerating drug development. A recent publication compared the processes for allowing accelerated marketing authorisations during the COVID‑19 pandemic. The authors highlighted that US and EU regulators were equally effective at accelerating “market access to Covid-19 medicines during the pandemic” without compromising safety or efficacy. However, there were some notable differences. While the EMA’s conditional marketing authorisation only covers first approvals of new treatments, the FDA’s covers “new indications of already-approved treatments”19, ie, repurposing. Repurposing of currently marketed products, eg, methotrexate,20 was an important and effective strategy in combatting COVID-19, particularly in the early stages prior to effective vaccines being developed. During the COVID-19 pandemic (March 2023 – May 2023) the EMA Emergency Task Force (ETF) coordinated and facilitated rapid regulatory activities “for the development, authorisation and safety monitoring of treatments and vaccines intended for the treatment and prevention of COVID-19”.21 These “exceptional measures are no longer applicable, but they may be considered in case of any future public health emergencies”.21 Similar strategies were applied by FDA and other regulatory agencies.22,23
Dissolution
In EPR Issue 4 2023 the “key role that dissolution testing has in the quality control of pharmaceutical drug products, its relevance for poorly soluble compounds, and how its limitations can impact determination of bioavailability”24 was examined. The FDA, in its “Overview of Major Quality Deficiencies and Approaches Available in GDUFA III” (generic drug user fee amendments) identified dissolution testing as one of its major quality deficiencies during 2023. In particular:
a “new in vitro dissolution (release) analytical method, including development report and validation, is required” as the proposed dissolution method is inadequate
“data supporting the proposed in vitro release acceptance criteria (eg, in vitroin vivo correlation (IVIVC) data or in silico physiologically based pharmacokinetics (PBPK) modelling) is inadequate”.25
Sun et al.26 assessed FDA field reports between 23005 and 2014 and highlighted that poorly soluble instant release (IR) drug products showed the most dissolution test failures, followed by poorly soluble modified release (MR) drug products and then highly soluble MR drug products.
Lipid-based drug delivery systems (LBDDS)
In EPR Issue 5 2023, lipid-based drug delivery systems (LBDDS) were examined. LBDDS formulations enhance the bioavailability of poorly soluble drugs and “have a proven track record of innovative and commercial success”.27 However, these systems often exhibit poor thermodynamic and/or kinetic stability, which can lead to phase separation on storage.28 In the final quarter of 2023, FDA highlighted that Novartis had issued a voluntary US nationwide recall29 of two batches of Sandimmune® oral solution (Cyclosporine Oral Solution, USP), 100 mg/mL, due to crystallisation. This highlights that even for well established LBDDS formulations, issues arising from thermodynamic instability can still occur.
Conclusions
Of the five major topics covered during 2023, it is likely that all will feature to a greater or lesser extent during 2024. However, N-nitrosamine contamination of drug products will continue to be the principal challenge facing the pharmaceutical industry over this coming year. It is to be hoped that a further revision of ICH M7 will help to address some of the fundamental issues and harmonise regulatory requirements.
References
Elder DP. Nitrosamines: the beginning of the end? Eur Pharm Rev. 2023; 28(3): 05.
Schlingemann J, Burns MJ, Ponting DJ, et al. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals. J Pharm Sci. 2023; 112: 1287-1304.
Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. 02 October 2023 EMA/409815/2020 Rev.19.
Snodin DJ. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines. Reg Toxicol Pharmacol. 2023; 141: 105403.
Dobo KL, Kenyon MO, Dirat O, et al. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine Impurities. Res. Toxicol. 2022, 35, 3, 475–489.
Fine J, Allain L, Schlingemann J, et al. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage. Reg Pharm Toxicol. 2023; 145: 105505.
Recommended Acceptable Intake Limits for Nitrosamine Drug SubstanceRelated Impurities (NDSRIs) FDA Guidance for Industry. August 2023.
Chakravarti S, Saiakhov RD, Girireddy M. Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines. Comput Toxicol. 2004; 29: 100298.
ICH M7(R2). ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENICRISK. Final version Adopted on 3 April 2023.
Schmidtsdorff S, Neumann J, Schmidt AH, Parr MK. Risk assessment for nitrosated pharmaceuticals: A future perspective in drug development. Arch Pharm DPhG. 2022; 355: e2100435.
Elder DP. New quality requirements for tobacco products. Eur Pharm Rev. 2023; 28(2): 05.
Wu Y, Levons J, Narang AS, et al. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility. AAPS PharmSciTech. 2011 Dec;12(4):1248-63.
Ghadanian M, Schafheutle E. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid‑19 Medicines and their Utilized Regulations. Therap Innov & Reg Sci. 2024; 58: 79–113.
Chen Y-T, Chang Y-H, Pathak N, et al. Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model. Fron Immunol. 2022: 13; 1080897.
EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines [OBSOLETE]. 2 June 2023 EMA/213341/2020 Rev.5.
Novack GD. Expedited regulatory product approval in the time of COVID-19. Ocul Surf. 2022 Oct; 26: 345–348.
Ireland K. Overview of Major Quality Deficiencies and Approaches Available in GDUFA III. Generic Drugs Forum 2023 – April 13, 2023.
Sun D, Hu M, Browing M, et al. Dissolution Failure of Solid Oral Drug Products in Field Alert Reports. J Pharm Sci. 2017; 106(5): 1302-1309.
Elder DP. Lipid-based drug delivery systems (LBDDS). Eur Pharm Rev. 2023; 28(6): 5.
Rahman MA, Harwansh R, Mirza MA, et al. Oral lipid-based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr Drug Deliv. 2011; 8(4): 330-345.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.